Bristol-Myers Squibb (XTRA:BRM) - Cotización, noticias y análisis

Resumen de acción BRM

Bristol-Myers Squibb Company descubre, desarrolla, licencia, fabrica, comercializa, distribuye y vende productos biofarmacéuticos en todo el mundo.

Acerca de la empresa

BRM fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	0/6
Financial Health	3/6
Dividends	5/6

Recompensas

Cotiza un 68% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 9.94%

Análisis de riesgos

El dividendo de 5.37% no está bien cubierto por los beneficios

Tiene un alto nivel de endeudamiento

Competidores de Bristol-Myers Squibb Company

Merck KGaA

XTRA:MRK

€66.1b

Bayer

XTRA:BAYN

€27.5b

Dermapharm Holding

XTRA:DMP

€1.8b

GSK

LSE:GSK

UK£70.7b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Bristol-Myers Squibb
Historical stock prices
Current Share Price	US$40.74
52 Week High	US$64.10
52 Week Low	US$40.64
Beta	0.39
1 Month Change	-14.48%
3 Month Change	-10.36%
1 Year Change	-33.76%
3 Year Change	-23.32%
5 Year Change	-1.25%
Change since IPO	-39.19%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	BRM	DE Pharmaceuticals	Mercado DE
7D	-3.8%	0.9%	-1.0%
1Y	-33.8%	-27.7%	2.0%

Rentabilidad vs. Industria: BRM obtuvo unos resultados inferiores a los del sector German Pharmaceuticals , que el año pasado arrojó un rendimiento del -28.2%.

Rentabilidad vs. Mercado: BRM obtuvo unos resultados inferiores a los del mercado German, que fue del 2.3% el año pasado.

Volatilidad de los precios

Is BRM's price volatile compared to industry and market?
BRM volatility
BRM Average Weekly Movement	3.7%
Pharmaceuticals Industry Average Movement	7.2%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: BRM no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de BRM (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1887	34,100	Chris Boerner	www.bms.com

Bristol-Myers Squibb Company descubre, desarrolla, licencia, fabrica, comercializa, distribuye y vende productos biofarmacéuticos en todo el mundo. Ofrece productos para enfermedades hematológicas, oncológicas, cardiovasculares, inmunológicas, fibróticas y neurocientíficas. Los productos de la empresa incluyen Eliquis para la reducción del riesgo de ictus/embolia sistémica en la fibrilación auricular no valvular, y para el tratamiento de la TVP/EP; Opdivo para diversas indicaciones contra el cáncer, como el de vejiga, sangre, CCR, cabeza y cuello, CCR, CHC, pulmón, melanoma, MPM, estómago y esófago; Pomalyst/Imnovid para el mieloma múltiple; Orencia para la artritis reumatoide activa y la artritis psoriásica; y Sprycel para el tratamiento de la leucemia mieloide crónica con cromosoma Filadelfia positivo.

Resumen de fundamentos de Bristol-Myers Squibb Company

¿Cómo se comparan los beneficios e ingresos de Bristol-Myers Squibb con su capitalización de mercado?
Estadísticas fundamentales de BRM
Capitalización bursátil	€82.83b
Beneficios(TTM)	-€5.71b
Ingresos (TTM)	€42.30b

2.0x

Ratio precio-ventas (PS)

-14.5x

Ratio precio-beneficio (PE)

¿Está BRM sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BRM
Ingresos	US$45.53b
Coste de los ingresos	US$10.92b
Beneficio bruto	US$34.62b
Otros gastos	US$40.77b
Beneficios	-US$6.15b

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

Jul 26, 2024

Beneficios por acción (BPA)	-3.03
Margen bruto	76.03%
Margen de beneficio neto	-13.50%
Ratio deuda/patrimonio	336.5%

¿Cómo se ha desempeñado BRM a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

5.5%

Rentabilidad actual por dividendo

-78%

Ratio de pagos

Resumen de acción BRM

Recompensas

Análisis de riesgos

Competidores de Bristol-Myers Squibb Company

XTRA:MRK

€66.1b

XTRA:BAYN

€27.5b

XTRA:DMP

€1.8b

LSE:GSK

UK£70.7b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings released: US$5.89 loss per share (vs US$1.08 profit in 1Q 2023)

First quarter 2024 earnings released: US$5.89 loss per share (vs US$1.08 profit in 1Q 2023)

First quarter 2024 earnings released: US$5.89 loss per share (vs US$1.08 profit in 1Q 2023)

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

Recent updates

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings released: US$5.89 loss per share (vs US$1.08 profit in 1Q 2023)

First quarter 2024 earnings released: US$5.89 loss per share (vs US$1.08 profit in 1Q 2023)

First quarter 2024 earnings released: US$5.89 loss per share (vs US$1.08 profit in 1Q 2023)

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Upcoming dividend of US$0.60 per share

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

Fourth quarter dividend of US$0.60 announced

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

Bristol-Myers Squibb Company Announces Management Changes

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Full year 2023 earnings released: EPS: US$3.88 (vs US$2.97 in FY 2022)

Bristol-Myers Squibb Company Announces Three Regulatory Acceptances from the U.S. Food and Drug Administration (FDA) and Japan’S Ministry of Health, Labour and Welfare (MHLW) for Breyanzi

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 CheckMate -67T Trial

Bristol-Myers Squibb Company Receives Positive Chmp Opinion for Car T Cell Therapy Abecma (Idecabtagene Vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Bristol Myers Squibb Announces Results from the Phase 3 Randomized Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

Bristol Myers Squibb Data At Asco Gu 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

European Medicines Agency Validates Bristol Bristol-Myers Squibb Company Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic Ros1-Positive Non-Small Cell Lung Cancer and Ntrk-Positive Solid Tumors

Upcoming dividend of US$0.60 per share at 4.7% yield

Bristol-Myers Squibb Company (NYSE:BMY) entered into definitive merger agreement to acquire RayzeBio, Inc. (NasdaqGM:RYZB) for $3.8 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Bristol-Myers Squibb Company to Report Q4, 2023 Results on Feb 02, 2024

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 Commands Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes At Ash 2023

Bristol-Myers Squibb Company Presents New Data At ASH 2023 Demonstrating Clinical Benefit Across B-Cell Malignancies with Breyanzi as A Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia

Bristol-Myers Squibb Company Announces Phase 3 Checkmate -8Hw Trial Evaluating Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary

Bristol Myers Squibb Announces U.S. Food and Drug Administration Accept the Supplemental Biologics License Application for Opdivo (nivolumab)

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bristol Myers Squibb Appoints Christopher Boerner as Chief Executive Officer

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Bristol-Myers Squibb Company Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.94 (vs US$0.75 in 3Q 2022)

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 Checkmate -77T Trial

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Early Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types At Esmo2023

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Upcoming dividend of US$0.57 per share at 3.9% yield

Bristol-Myers Squibb Company to Report Q3, 2023 Results on Oct 26, 2023

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer